# RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

- Source: PR Newswire
- Published: 2026-10-25T13:45:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer-302918746.html
- Canonical: https://groundlevelnews.com/story/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demons-00886b/

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._